CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Rocket Pharmaceuticals, Inc.

RCKT
$1.40B
Small Cap
NASDAQPharmaceutical Preparations🇺🇸North AmericaNEW YORK299 employees

Drugs in Pipeline

2

Phase 3 Programs

0

Upcoming Catalysts

1

Next Catalyst

May 5, 2026

7d

Market Overview

Stock performance and key metrics

RCKT News
Catalyst Timeline

1 upcoming, 1 past

Phase 2Next

RP-L102 Phase 2 Results Expected

May 5, 2026RP-L1025

Primary completion for RP-L102 trial (NCT04248439) in Fanconi Anemia Complementation Group A

Source
Drug Pipeline

RP-L201

Phase 2

Leukocyte Adhesion Defect - Type I

RP-L102

Phase 2

Fanconi Anemia Complementation Group A

Fanconi Anemia Complementation Group A

1 drug in this indication

Leukocyte Adhesion Defect - Type I

1 drug in this indication

Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)

Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply